Inhaled treprostinil and the vascular turn in pulmonary fibrosis

TETON trials recently evaluated inhaled treprostinil in idiopathic pulmonary fibrosis (IPF) using two parallel phase 3 studies in different world regions. Both met the primary endpoint, demonstrating significantly less one-year forced vital capacity decline versus placebo. This viewpoint critically appraises the findings and contextualizes them within the evolving IPF treatment landscape.